{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:27:21Z","timestamp":1792301241751,"version":"4.4.0"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Anti-M\u00fcllerian hormone (AMH) has become one of the most informative biochemical markers of the ovary and is considered the earliest and most sensitive marker of reproductive aging. The accuracy of AMH in predicting ovarian response to controlled ovarian stimulation has led to AMH-based prognostication counseling and individualization of assisted reproductive technology (ART) stimulation protocols to optimize ovarian response and minimize hyperstimulation risks. Although AMH is considered a good predictor of quantitative ART outcomes, its correlation with qualitative ART outcomes is still controversial. The aim of this review is to provide an updated overview of the clinical utility of AMH in predicting ART outcomes.<\/jats:p>","DOI":"10.1097\/grf.0000000000000436","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T11:40:31Z","timestamp":1555587631000},"page":"238-256","source":"Crossref","is-referenced-by-count":29,"title":["Anti-M\u00fcllerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes"],"prefix":"10.1097","volume":"62","author":[{"given":"EMILY","family":"GRANGER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RESHEF","family":"TAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajog.2017.02.027","article-title":"Ovarian reserve testing: a user's guide","volume":"217","author":"Tal","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0015-0282(01)03201-0","article-title":"Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles","volume":"77","author":"Seifer","year":"2002","journal-title":"Fertil Steril"},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/humrep\/dey077","article-title":"Anti-Mullerian hormone levels and incidence of early natural menopause in a prospective study","volume":"33","author":"Bertone-Johnson","year":"2018","journal-title":"Hum Reprod"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2011-3032","article-title":"Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women","volume":"97","author":"Freeman","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"59.e51","DOI":"10.1016\/j.ajog.2014.02.026","article-title":"Characterization of women with elevated antimullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes","volume":"211","author":"Tal","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijgo.12167","article-title":"Review of clinical indicators, including serum anti-Mullerian hormone levels, for identification of women who should consider egg freezing","volume":"138","author":"Martyn","year":"2017","journal-title":"Int J Gynaecol Obstet"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/humupd\/dmp036","article-title":"Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)","volume":"16","author":"La Marca","year":"2010","journal-title":"Hum Reprod Update"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/humrep\/der318","article-title":"Predictive factors of ovarian response and clinical outcome after IVF\/ICSI following a rFSH\/GnRH antagonist protocol with or without oral contraceptive pre-treatment","volume":"26","author":"Andersen","year":"2011","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.fertnstert.2013.04.029","article-title":"Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization\/intracytoplasmic sperm injection","volume":"100","author":"Polyzos","year":"2013","journal-title":"Fertil Steril"},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.fertnstert.2014.12.114","article-title":"Comparison of antimullerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials","volume":"103","author":"Nelson","year":"2015","journal-title":"Fertil Steril"},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.fertnstert.2012.12.048","article-title":"Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients","volume":"99","author":"Arce","year":"2013","journal-title":"Fertil steril"},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/humupd\/dms043","article-title":"The ageing ovary and uterus: new biological insights","volume":"19","author":"Nelson","year":"2013","journal-title":"Hum Reprod Update"},{"key":"R13-20230911","first-page":"3836","article-title":"Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of sertoli and granulosa cells","volume":"84","author":"Rajpert-De Meyts","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"e22024","DOI":"10.1371\/journal.pone.0022024","article-title":"A validated model of serum anti-mullerian hormone from conception to menopause","volume":"6","author":"Kelsey","year":"2011","journal-title":"PloS One"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rbmo.2016.04.007","article-title":"The role of AMH in the pathophysiology of polycystic ovarian syndrome","volume":"33","author":"Garg","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/rep.1.00529","article-title":"Anti-Mullerian hormone: a new marker for ovarian function","volume":"131","author":"Visser","year":"2006","journal-title":"Reproduction (Cambridge, England)"},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1210\/endo.140.12.7204","article-title":"Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary","volume":"140","author":"Durlinger","year":"1999","journal-title":"Endocrinology"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.fertnstert.2009.07.1674","article-title":"Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles","volume":"94","author":"Sowers","year":"2010","journal-title":"Fertil Steril"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"959487","DOI":"10.1155\/2013\/959487","article-title":"How much does AMH really vary in normal women?","volume":"2013","author":"La Marca","year":"2013","journal-title":"Int J Endocrinol"},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.fertnstert.2013.04.024","article-title":"Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis","volume":"100","author":"Broer","year":"2013","journal-title":"Fertil Steril"},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/humupd\/dms041","article-title":"Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach","volume":"19","author":"Broer","year":"2013","journal-title":"Hum Reprod Update"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmr037","article-title":"The poor responder in IVF: is the prognosis always poor?: a systematic review","volume":"18","author":"Oudendijk","year":"2012","journal-title":"Hum Reprod Update"},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/00016340701194948","article-title":"The probability of successful IVF outcome after poor ovarian response","volume":"86","author":"Saldeen","year":"2007","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.fertnstert.2015.10.004","article-title":"Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimullerian hormone: a multivariate analysis of over 5000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013","volume":"105","author":"Seifer","year":"2016","journal-title":"Fertil Steril"},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.fertnstert.2013.12.039","article-title":"Value of antimullerian hormone as a prognostic indicator of in vitro fertilization outcome","volume":"101","author":"Reichman","year":"2014","journal-title":"Fertil Steril"},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/j.fertnstert.2017.07.686","article-title":"Prevalence of ovarian hyperstimulation syndrome (OHSS) and hypercoagulability in patients triggered by GnRH agonist for excessive follicular response: a systematic follow-up","volume":"108","author":"Peigne","year":"2017","journal-title":"Fertil Steril"},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10815-017-0990-7","article-title":"What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study","volume":"34","author":"Tarlatzi","year":"2017","journal-title":"J Assis Reprod Genet"},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"1065.e1061","DOI":"10.1016\/j.fertnstert.2018.01.039","article-title":"Antimullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies","volume":"109","author":"Lyttle Schumacher","year":"2018","journal-title":"Fertil Steril"},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/humrep\/del127","article-title":"Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles","volume":"21","author":"Ebner","year":"2006","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5935\/1518-0557.20170035","article-title":"The predictive value of serum concentrations of anti-Mullerian hormone for oocyte quality, fertilization, and implantation","volume":"21","author":"Borges","year":"2017","journal-title":"JBRA Assist Reprod"},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"777.e772","DOI":"10.1016\/j.fertnstert.2017.08.029","article-title":"Female age, serum antimullerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization\/intracytoplasmic sperm injection cycles","volume":"108","author":"La Marca","year":"2017","journal-title":"Fertil Steril"},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.rbmo.2018.04.039","article-title":"Low anti-Mullerian hormone concentration is associated with increased risk of embryonic aneuploidy in women of advanced age","volume":"37","author":"Jiang","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.fertnstert.2014.09.041","article-title":"Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis","volume":"103","author":"Tal","year":"2015","journal-title":"Fertil Steril"},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10815-014-0193-4","article-title":"Anti-M\u00fcllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF","volume":"31","author":"Lehmann","year":"2014","journal-title":"J Assist Reprod Genet"},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/humrep\/dei270","article-title":"Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology","volume":"21","author":"Silberstein","year":"2006","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R37-20230911","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1210\/jc.2006-1053","article-title":"Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization","volume":"92","author":"Fanchin","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1093\/humrep\/der271","article-title":"Anti-Mullerian hormone\u2014is it a crystal ball for predicting ovarian ageing?","volume":"26","author":"Loh","year":"2011","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R40-20230911","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmu003","article-title":"The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature","volume":"20","author":"Iliodromiti","year":"2014","journal-title":"Hum Reprod Update"},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.rbmo.2018.03.015","article-title":"Very low anti-mullerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate","volume":"37","author":"Pacheco","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.fertnstert.2017.10.021","article-title":"Antimullerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013","volume":"109","author":"Tal","year":"2018","journal-title":"Fertil Steril"},{"key":"R43-20230911","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.fertnstert.2015.05.004","article-title":"Personalized prediction of live birth: are we there yet?","volume":"104","author":"Seifer","year":"2015","journal-title":"Fertil Steril"},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/humrep\/deu053","article-title":"Association between response to ovarian stimulation and miscarriage following IVF: an analysis of 124 351 IVF pregnancies","volume":"29","author":"Sunkara","year":"2014","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.rbmo.2009.11.005","article-title":"Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation","volume":"20","author":"Haadsma","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"R46-20230911","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.rbmo.2017.06.027","article-title":"Significant correlation between anti-mullerian hormone and embryo euploidy in a subpopulation of infertile patients","volume":"35","author":"Gat","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"R47-20230911","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.fertnstert.2017.07.001","article-title":"Serum antimullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer","volume":"108","author":"Tarasconi","year":"2017","journal-title":"Fertil Steril"},{"key":"R48-20230911","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/humrep\/den480","article-title":"Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception","volume":"24","author":"Nelson","year":"2009","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R49-20230911","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/humrep\/der182","article-title":"Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF","volume":"26","author":"Yates","year":"2011","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R50-20230911","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil Steril"},{"key":"R51-20230911","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"R52-20230911","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.rbmo.2013.07.008","article-title":"Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH","volume":"27","author":"Lan","year":"2013","journal-title":"Reprod Biomed Online"},{"key":"R53-20230911","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/humrep\/dex012","article-title":"The addition of anti-Mullerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial","volume":"32","author":"Magnusson","year":"2017","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R54-20230911","first-page":"CD012693","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","volume":"2","author":"Lensen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R55-20230911","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/humrep\/dep436","article-title":"Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT)","volume":"25","author":"Lainas","year":"2010","journal-title":"Hum Reprod (Oxford, England)"},{"key":"R56-20230911","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Banga","year":"2017","journal-title":"Hum Reprod Update"},{"key":"R57-20230911","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1472-6483(10)61053-X","article-title":"Anti-Mullerian hormone as a predictor of IVF outcome","volume":"14","author":"Lekamge","year":"2007","journal-title":"Reprod Biomed Online"},{"key":"R58-20230911","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.fertnstert.2006.06.019","article-title":"Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection","volume":"87","author":"Smeenk","year":"2007","journal-title":"Fertil Steril"},{"key":"R59-20230911","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1472-6483(10)60480-4","article-title":"Anti-Mullerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?","volume":"16","author":"Lie Fong","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"R60-20230911","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ando.2009.03.007","article-title":"Serum antimullerian hormone is not predictive of oocyte quality in vitro fertilization","volume":"70","author":"Guerif","year":"2009","journal-title":"Ann Endocrinol"},{"key":"R61-20230911","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejogrb.2010.02.029","article-title":"The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos","volume":"150","author":"Majumder","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R62-20230911","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00404-011-1979-6","article-title":"Different serum anti-Mullerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes","volume":"284","author":"Irez","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R63-20230911","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.fertnstert.2010.07.1042","article-title":"Anti-Mullerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation","volume":"95","author":"Riggs","year":"2011","journal-title":"Fertil Sterility"},{"key":"R64-20230911","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10815-013-9973-5","article-title":"The predictive value of anti-Mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET)","volume":"30","author":"Lin","year":"2013","journal-title":"J Assist Reprod Genet"},{"key":"R65-20230911","first-page":"231","article-title":"Assessment of the relationship of basal serum anti-mullerian hormone levels with oocyte quality and pregnancy outcomes in patients undergoing ICSI","volume":"13","author":"Aydin","year":"2015","journal-title":"Iran J Reprod Med"},{"key":"R66-20230911","first-page":"225","article-title":"Anti-Mullerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation","volume":"69","author":"Melado Vidales","year":"2017","journal-title":"Minerva Ginecol"},{"key":"R67-20230911","first-page":"1755","article-title":"The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF\/ICSI: a meta-analysis","volume":"8","author":"Yao","year":"2015","journal-title":"Int J Clin Exp Med"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003081-201906000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:12:36Z","timestamp":1694419956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003081-201906000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000436","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}